NCT00771615View on ClinicalTrials.gov

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

469

Participants

Timeline

Start Date

October 16, 2008

Primary Completion Date

May 26, 2009

Study Completion Date

December 4, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

GSK A/turkey H5N1 Influenza vaccine

One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.

Trial Locations (10)

30281

GSK Investigational Site, Stockbridge

33143

GSK Investigational Site, Miami

35802

GSK Investigational Site, Huntsville

59801

GSK Investigational Site, Missoula

66219

GSK Investigational Site, Lenexa

89130

GSK Investigational Site, Las Vegas

92801

GSK Investigational Site, Anaheim

B3K 6R8

GSK Investigational Site, Halifax

B2N 1L2

GSK Investigational Site, Truro

J1H 4J6

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY